http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2760174-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d584042a524740a406723fe1631e49e5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2021-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8684e5d45c876d802aec6052dbdeb5de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8a831808f7329de6082ed3e2862354e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eecc407bc478d90f3e34e10aa3849f24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1675549d0ad981b77f53284487927c03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7b02380690d685f611f2716d603458a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d4385c87d93888bd562cd11c99780dd |
| publicationDate | 2021-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2760174-C1 |
| titleOfInvention | Method for combined treatment of metastatic colorectal cancer in patients with resectable hepatic metastases and in presence of mutations in kras and braf genes |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to the field of medicine, namely to oncology, and can be used for combined treatment of metastatic colorectal cancer in patients with resectable hepatic metastases and in the presence of mutations in the KRAS and BRAF genes. The method includes drop administration of bevacizumab 5 mg/kg intravenously on day 1, irinotecan 165 mg/m2intravenously on day 1, oxaliplatin 85 mg/m2intravenously on day 1, leucovorin 200 mg/m2intravenously on day 1, and 5-fluorouracil 3,200 mg/m2intravenously. Three courses of preoperative treatment are conducted, wherein leucovorin infusion is conducted on days 1 and 2 at a dose of 200 mg/m2, 5-fluorouracil is administered for 46 hours, the interval between the courses is 12 days. After completing the preoperative treatment, in the presence of an objective tumour response, simultaneous radical surgery is performed on the primary tumour and on the metastatic foci in the liver R0, 3 courses of adjuvant treatment are conducted in the postoperative period according to the previous scheme, but without administering bevacizumab.EFFECT: use of the invention provides a possibility of improving the results of combined treatment of metastatic colorectal cancer with isolated liver damage by increasing the frequency of objective responses of the tumour and reducing the amount of adverse events during medicinal anti-tumour treatment, increasing the frequency of performing parenchyma-preserving radical liver resections (R0), as well as increasing the overall and relapse-free survival of patients.1 cl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2797847-C1 |
| priorityDate | 2021-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.